New Gene Expression Test Helps Guide Atopic Dermatitis Treatment Decisions
Castle Biosciences’ AdvanceAD-Tx test identifies patients more likely to respond to JAK inhibitor therapy versus Th2-targeted treatments.
Read MorePosted by CLP Edit Staff | Feb 20, 2026 | Allergy & Autoimmune |
Castle Biosciences’ AdvanceAD-Tx test identifies patients more likely to respond to JAK inhibitor therapy versus Th2-targeted treatments.
Read MorePosted by CLP Edit Staff | Feb 18, 2026 | Disease States |
Researchers have identified blood biomarkers that may enable detection of Parkinson’s disease up to 20 years before symptoms.
Read MorePosted by CLP Edit Staff | Feb 18, 2026 | Lung Cancer |
The NeXT Personal molecular residual disease test can now be used for surveillance of patients with Stage I to III non-small cell lung cancer.
Read MorePosted by CLP Edit Staff | Feb 18, 2026 | Colorectal |
Guardant Health will provide up to 100 free Shield blood tests per organization to support colorectal cancer screening events and outreach during Colorectal Cancer Awareness Month in March.
Read MorePosted by CLP Edit Staff | Feb 17, 2026 | Cancer |
The CLIA-certified facility offers functional precision medicine testing that analyzes live tumor cells against FDA-approved therapies within 10 days.
Read More